Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry

Study Overview
=================
Brief Summary
-----------------
Long-term prognostic value of macrovascular and microvascular coronary artery stenoses in each type of cardiomyopathy.

Detailed Description
-----------------
Coronary artery imaging techniques have taken a central role in the assessment of cardiovascular (CV) diagnosis over the past two decades. Many patients with a cardiomyopathy are also found to have a bystander coronary artery disease, not responsible for their cardiomyopathy. However, the prognostic value of those bystander coronary artery diseases is not known. Also, new imaging techniques have been developed to assess coronary microvascular disease, but the prognostic value of these findings is not known. In this study, the investigators evaluate the incidence and the prognosis of bystander coronary artery disease and microvascular disease in patients with ischemic, hypertrophic, dilated and restrictive cardiomyopathies in 5 French centers. Coronary angiography, cardiac magnetic resonance (CMR), tomographic coronary artery angiography, single-photon emission computed tomography (SPECT), rest and stress trans-thoracic echocardiography (TTE) results will be recorded. Macrovascular coronary artery disease is defined by : a stenosis > 50 % in coronary angiography confirmed with myocardial ischemia (SPECT, stress echocardiography), a stenosis > 70 % (50% if it is the left main coronary artery) or a stenosis 30-70 % with a fractional flow reserve (FFR) < 0.8 Microvascular disease is defined by an index of microvascular resistance (IMR) >23 or myocardial perfusion heterogeneity imaging (MPHI) > 4 using SPECT or CMR. Major adverse cardiovascular events (MACE) will be assessed 1 year, 2 years and 5 years after enrollment.

Official Title
-----------------
Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry

Conditions
-----------------
Hypertrophic, Ischemic, Restrictive Cardiomyopathy, Dilated Cardiomyopathies

Intervention / Treatment
-----------------
* Other: Patients with a cardiomyopathy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ischemic Dilated Hypertrophic Restrictive cardiomyopathy. Exclusion Criteria: Pregnant women Breastfeeding women Patients under legal protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Patients with a cardiomyopathy|Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major Adverse Cardiovascular Events | Composite outcome = rate of cardiovascular death, non-fatal myocardial infarction, need for myocardial revascularization by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) > 3 months after enrollment. During follow up | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiomyopathy, Multimodal imaging, Coronary artery disease, Coronary microvascular disease, Prognosis, Atherosclerosis, Myocardial ischemia